People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.2M | 2018 |
| Sideris Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $17.6M | $578.1M | 2013 |
| CoStim Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.9M | 2013 |
| Mitokyne, Inc. | — | Pharmaceuticals | Series A | $5.2M | $161.7M | 2013 |
Kazumi Shiosaki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kazumi Shiosaki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 2 | 12 |
| Marian Nakada | 2 | 4 |
| Jean-Francois Formela | 1 | 17 |
| Briggs Morrison | 1 | 8 |
| Michal Silverberg | 1 | 7 |
| Josh Resnick | 1 | 7 |
| Ansbert Gadicke | 1 | 7 |
| David Cordo | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| Roger Kitterman | 1 | 5 |
| Ansbert K Gadicke | 1 | 4 |
| Richard Aldrich | 1 | 3 |
| Robert Millman | 1 | 3 |
| Christine Brennan | 1 | 3 |
| Henrijette Richter | 1 | 2 |
| Carolyn Ng | 1 | 2 |
| Douglas K Reed | 1 | 2 |
| Thomas Neenan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.